Who
Jennifer Buell
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, MiNK Therapeutics; Chairman Executive Council, Agenus; Director, Performance Technologies.
In numbers
- Trades disclosed
- 56
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $85K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 3 Sep 2017
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Sold | $73K6,938 at $10.56 | filing |
| 11 Oct 2026filed 14 Oct 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code M | —23,191 | filing |
| 11 Oct 2026filed 14 Oct 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —23,191 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Jan 2026filed 14 Jan 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code F | $111K10,024 at $11.12 | filing |
| 2 Jan 2026filed 14 Jan 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code F | $111K10,024 at $11.12 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $350K31,474 at $11.12 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $350K31,474 at $11.12 | filing |
| 9 Sep 2025filed 3 Oct 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code F | $82K5,351 at $15.36 | filing |
| 9 Sep 2025filed 11 Sep 2025 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Sep 2025filed 11 Sep 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $280K18,229 at $15.36 | filing |
| 2 May 2025filed 6 May 2025 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $1,807581 at $3.11 | filing |
| 18 Apr 2025filed 5 May 2025 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $1,808869 at $2.08 | filing |
News
No headline names them, or the companies they trade most, lately.